Navigation Links
CureDM's Diabetes Therapy Achieves Major Development Milestone
Date:4/30/2008

WYNNEWOOD, Pa., April 30 /PRNewswire/ -- CureDM, Inc., a biopharmaceutical company developing new therapies that prevent, ameliorate, or reverse both type 1 and 2 diabetes, announces its achievement of a major drug development milestone for Human proIslet Peptide (HIP). CureDM has successfully stabilized HIP to improve its bioavailability with recent dose response studies indicating that the dosage used in man may be as much as 100-fold lower than the native form. HIP is a 14-amino acid human peptide derived from a specific human gene responsible for populating the pancreas with islets, which contain the cells that secrete insulin and other hormones necessary to prevent diabetes.

"Meeting this milestone has a significant impact on the commercial value of Human proIslet Peptide," according to Loraine V. Upham, CEO. "Not only does this mean lower costs associated with the manufacture and commercialization, but also potentially better safety and tolerability outcomes in human trials." CureDM has filed with the FDA and anticipates approval for commencement of human studies in early 2009.

Further studies are underway to determine just how low of a dose is possible. Previous studies have confirmed that the stabilization of HIP did not adversely affect the efficacy and demonstrated that normal glucose levels were achieved after 25 days of treatment and remained normal after the therapy was stopped.

About HIP

Human proIslet Peptide (HIP) stimulates the differentiation of pancreatic progenitor cells, which are present in the adult pancreas, into new insulin-producing islets. Each new islet contains pools of beta cells which make insulin. It is hypothesized that treatment with this therapeutic will restore human pancreatic function without the use of stem cells.

About CureDM

The CureDM approach to restore new insulin-producing cells through islet neogenesis can potentially reverse both type 1 and type 2 diabetes. Patients with type 1 diabetes will require pretreatment with an immune tolerance agent to protect new islets formed by HIP. CureDM, Inc., located at the Lankenau Institute for Medical Research on the Lankenau Hospital campus in Wynnewood, PA, is developing peptide therapeutics using a platform that combines bioinformatics, proteomics and Human Genome sequence data. This method has enabled the CureDM scientific team to determine the proteins involved in, and probable mechanisms of islet neogenesis in humans. For more information about CureDM, visit http://www.curedm.com.


'/>"/>
SOURCE CureDM, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Drug Combo Could Lower Diabetes Complications and Costs
2. Discovery Leads to Earlier Diagnosis of Type 1 Diabetes
3. People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
4. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
5. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
6. Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease
7. Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)
8. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. New York-Presbyterian/Weill Cornell is First New York Medical Center to Offer Tantalus Clinical Trial to Diabetes Patients
11. Reduced Lung Capacity Accelerates With Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... N.Y. , May 5, 2017  Hill-Rom Holdings, ... will add approximately 100,000 square feet to its Welch ... September 2016 its commitment to bring more than 100 ... , where Welch Allyn has maintained a significant presence ... help accommodate these new positions, a large portion of ...
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 3, 2017  Getinge, a leading global provider ... enhancement and cost efficiency within healthcare and life ... contemporary practice demonstrating that intra-aortic balloon counterpulsation (IABC) ... ill patients. The single-center, retrospective, observational study showed ... MEGA ® 50cc intra-aortic balloon (IAB) in ...
Breaking Medicine Technology:
(Date:5/26/2017)... York, NY (PRWEB) , ... May 26, 2017 , ... ... Health & Wound Care" campaign in USA Today, which will educate readers on how ... side of the campaign, a large focus is placed on melanoma. Dancing with the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Amir Qureshi, MD ... a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has ... are pleased to be the first in Arkansas to introduce the most powerful SCS ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for ... applications. “We are thrilled to partner with Cupron® to provide customers with ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... ... ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his ... of published authors, Bob and Margaret Massey. Bob Massey is small in stature but ... leather tough." His love for others is apparent in all of his life decisions. ...
Breaking Medicine News(10 mins):